MX2021015058A - Sistemas de casx artificiales. - Google Patents

Sistemas de casx artificiales.

Info

Publication number
MX2021015058A
MX2021015058A MX2021015058A MX2021015058A MX2021015058A MX 2021015058 A MX2021015058 A MX 2021015058A MX 2021015058 A MX2021015058 A MX 2021015058A MX 2021015058 A MX2021015058 A MX 2021015058A MX 2021015058 A MX2021015058 A MX 2021015058A
Authority
MX
Mexico
Prior art keywords
casx
variant
engineered
systems
gnas
Prior art date
Application number
MX2021015058A
Other languages
English (en)
Inventor
Benjamin Oakes
Sean Higgins
Hannah Spinner
Sarah Denny
Brett T Staahl
Kian Taylor
Katherine Baney
Isabel Colin
Maroof Adil
Original Assignee
Scribe Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scribe Therapeutics Inc filed Critical Scribe Therapeutics Inc
Publication of MX2021015058A publication Critical patent/MX2021015058A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C12N2320/11—Applications; Uses in screening processes for the determination of target sites, i.e. of active nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Abstract

En la presente se proporcionan sistemas de CasX y componentes de estos, incluidas proteínas CasX variantes y ácidos nucleicos guia variantes (ANg). Las proteínas CasX variantes y ANg variantes de la divulgación muestran por lo menos una característica mejorada cuando se los compara con una proteína CasX de referencia o un ANg de referencia de la divulgación. En algunas instancias, las variantes tienen una o más funciones mejoradas del complejo de ribonucleoproteínas de CasX. En algunas instancias, las variantes tienen una o más funciones mejoradas del complejo de ribonucleoproteínas de CasX.
MX2021015058A 2019-06-07 2020-06-05 Sistemas de casx artificiales. MX2021015058A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962858750P 2019-06-07 2019-06-07
US201962944892P 2019-12-06 2019-12-06
US202063030838P 2020-05-27 2020-05-27
PCT/US2020/036505 WO2020247882A1 (en) 2019-06-07 2020-06-05 Engineered casx systems

Publications (1)

Publication Number Publication Date
MX2021015058A true MX2021015058A (es) 2022-04-06

Family

ID=71899867

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021015058A MX2021015058A (es) 2019-06-07 2020-06-05 Sistemas de casx artificiales.

Country Status (16)

Country Link
US (3) US11560555B2 (es)
EP (1) EP3980533A1 (es)
JP (1) JP2022534809A (es)
KR (1) KR20220032050A (es)
CN (1) CN114375334A (es)
AU (1) AU2020289591A1 (es)
BR (1) BR112021024288A2 (es)
CA (1) CA3142883A1 (es)
CL (1) CL2021003233A1 (es)
GB (1) GB2600274A (es)
IL (1) IL288738A (es)
MX (1) MX2021015058A (es)
PE (1) PE20220256A1 (es)
SG (1) SG11202113253SA (es)
TW (1) TW202113074A (es)
WO (1) WO2020247882A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210309981A1 (en) * 2018-08-22 2021-10-07 Junjie Liu Variant type v crispr/cas effector polypeptides and methods of use thereof
SG11202113253SA (en) 2019-06-07 2021-12-30 Scribe Therapeutics Inc Engineered casx systems
US20220348925A1 (en) 2019-09-09 2022-11-03 Scribe Therapeutics Inc. Compositions and methods for the targeting of sod1
US20230033866A1 (en) 2019-12-06 2023-02-02 Scribe Therapeutics Inc. Compositions and methods for the targeting of rhodopsin
WO2021142342A1 (en) * 2020-01-10 2021-07-15 Scribe Therapeutics Inc. Compositions and methods for the targeting of pcsk9
KR20230002401A (ko) 2020-03-18 2023-01-05 스크라이브 테라퓨틱스 인크. C9orf72의 표적화를 위한 조성물 및 방법
US20240100185A1 (en) 2020-12-03 2024-03-28 Scribe Therapeutics Inc. Compositions and methods for the targeting of ptbp1
KR20230128289A (ko) 2020-12-03 2023-09-04 스크라이브 테라퓨틱스 인크. 조작된 클래스 2 유형 v crispr 시스템
JP2023552820A (ja) 2020-12-09 2023-12-19 スクライブ・セラピューティクス・インコーポレイテッド 遺伝子編集のためのａａｖベクター
EP4305158A1 (en) 2021-03-09 2024-01-17 Arbor Biotechnologies, Inc. Compositions comprising a variant polypeptide and uses thereof
US20230023791A1 (en) 2021-06-01 2023-01-26 Arbor Biotechnologies, Inc. Gene editing systems comprising a crispr nuclease and uses thereof
EP4351660A2 (en) 2021-06-09 2024-04-17 Scribe Therapeutics Inc. Particle delivery systems
TW202320864A (zh) 2021-09-21 2023-06-01 美商斯奎柏治療公司 經工程改造之ｃａｓｘ抑制子系統
AU2022349684A1 (en) 2021-09-23 2024-03-21 Scribe Therapeutics Inc. Self-inactivating vectors for gene editing
CN116497002A (zh) * 2022-01-19 2023-07-28 中国科学院动物研究所 工程化的CasX核酸酶、效应蛋白及其用途
WO2023235818A2 (en) 2022-06-02 2023-12-07 Scribe Therapeutics Inc. Engineered class 2 type v crispr systems
WO2023235888A2 (en) 2022-06-03 2023-12-07 Scribe Therapeutics Inc. COMPOSITIONS AND METHODS FOR CpG DEPLETION
WO2023240027A1 (en) 2022-06-07 2023-12-14 Scribe Therapeutics Inc. Particle delivery systems
WO2023240074A1 (en) 2022-06-07 2023-12-14 Scribe Therapeutics Inc. Compositions and methods for the targeting of pcsk9
WO2023240076A1 (en) 2022-06-07 2023-12-14 Scribe Therapeutics Inc. Compositions and methods for the targeting of pcsk9
WO2023240162A1 (en) 2022-06-08 2023-12-14 Scribe Therapeutics Inc. Aav vectors for gene editing
WO2023240157A2 (en) 2022-06-08 2023-12-14 Scribe Therapeutics Inc. Compositions and methods for the targeting of dmd
CN117296799B (zh) * 2023-11-28 2024-02-02 四川省医学科学院·四川省人民医院 一种视网膜色素变性疾病模型的构建方法及其应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5412087A (en) 1992-04-24 1995-05-02 Affymax Technologies N.V. Spatially-addressable immobilization of oligonucleotides and other biological polymers on surfaces
US5695937A (en) 1995-09-12 1997-12-09 The Johns Hopkins University School Of Medicine Method for serial analysis of gene expression
WO2010054007A1 (en) 2008-11-07 2010-05-14 Fabrus Llc Combinatorial antibody libraries and uses thereof
WO2010075303A1 (en) 2008-12-23 2010-07-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Splicing factors with a puf protein rna-binding domain and a splicing effector domain and uses of same
WO2012068627A1 (en) 2010-11-24 2012-05-31 The University Of Western Australia Peptides for the specific binding of rna targets
PL2800811T3 (pl) 2012-05-25 2017-11-30 Emmanuelle Charpentier Sposoby i kompozycje do kierowanej RNA modyfikacji docelowego DNA i do modulacji transkrypcji kierowanej RNA
US9234213B2 (en) 2013-03-15 2016-01-12 System Biosciences, Llc Compositions and methods directed to CRISPR/Cas genomic engineering systems
US9790490B2 (en) 2015-06-18 2017-10-17 The Broad Institute Inc. CRISPR enzymes and systems
FI3430134T3 (fi) 2015-06-18 2023-01-13 Uusia CRISPR-entsyymejä ja järjestelmiä
CA3024543A1 (en) 2015-10-22 2017-04-27 The Broad Institute, Inc. Type vi-b crispr enzymes and systems
WO2017083722A1 (en) 2015-11-11 2017-05-18 Greenberg Kenneth P Crispr compositions and methods of using the same for gene therapy
WO2017106569A1 (en) 2015-12-18 2017-06-22 The Regents Of The University Of California Modified site-directed modifying polypeptides and methods of use thereof
US9896696B2 (en) 2016-02-15 2018-02-20 Benson Hill Biosystems, Inc. Compositions and methods for modifying genomes
CA3029254A1 (en) 2016-06-24 2017-12-28 The Regents Of The University Of Colorado, A Body Corporate Methods for generating barcoded combinatorial libraries
WO2018035250A1 (en) 2016-08-17 2018-02-22 The Broad Institute, Inc. Methods for identifying class 2 crispr-cas systems
US11873504B2 (en) * 2016-09-30 2024-01-16 The Regents Of The University Of California RNA-guided nucleic acid modifying enzymes and methods of use thereof
US9982267B2 (en) 2016-10-12 2018-05-29 Feldan Bio Inc. Rationally-designed synthetic peptide shuttle agents for delivering polypeptide cargos from an extracellular space to the cytosol and/or nucleus of a target eukaryotic cell, uses thereof, methods and kits relating to same
WO2018132390A1 (en) 2017-01-10 2018-07-19 Christiana Care Health Services, Inc. Methods for in vitro site-directed mutagenesis using gene editing technologies
CA3050616A1 (en) 2017-03-24 2018-09-27 Curevac Ag Nucleic acids encoding crispr-associated proteins and uses thereof
US11773409B2 (en) 2017-04-21 2023-10-03 The Board Of Trustees Of The Leland Stanford Junior University CRISPR/Cas 9-mediated integration of polynucleotides by sequential homologous recombination of AAV donor vectors
WO2019084148A1 (en) 2017-10-25 2019-05-02 Monsanto Technology Llc TARGETED RNA GUIDED ENDONUCLEASE ENDONUCLEASE ACTIVITY IN EUKARYOTES
US10253365B1 (en) 2017-11-22 2019-04-09 The Regents Of The University Of California Type V CRISPR/Cas effector proteins for cleaving ssDNAs and detecting target DNAs
JP2021513866A (ja) 2018-02-27 2021-06-03 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル アンジェルマン症候群を処置する方法および組成物
US20200224160A1 (en) 2018-02-27 2020-07-16 Sorrento Therapeutics, Inc. Process for dna integration using rna-guided endonucleases
WO2019213273A1 (en) 2018-05-01 2019-11-07 The Children's Medical Center Corporation Enhanced bcl11a rnp / crispr delivery & editing using a 3xnls-cas9
US20210139892A1 (en) 2018-07-05 2021-05-13 The Regents Of The University Of California Compositions and methods for delivery of rna to a cell
WO2020023529A1 (en) 2018-07-24 2020-01-30 The Regents Of The University Of California Rna-guided nucleic acid modifying enzymes and methods of use thereof
US20210309981A1 (en) 2018-08-22 2021-10-07 Junjie Liu Variant type v crispr/cas effector polypeptides and methods of use thereof
WO2020247883A2 (en) 2019-06-07 2020-12-10 Scribe Therapeutics Inc. Deep mutational evolution of biomolecules
SG11202113253SA (en) 2019-06-07 2021-12-30 Scribe Therapeutics Inc Engineered casx systems
US20220315914A1 (en) 2019-07-08 2022-10-06 The Regents Of The University Of California Variant type v crispr/cas effector polypeptides and methods of use thereof
CN114340656A (zh) 2019-08-02 2022-04-12 孟山都技术公司 使用huh内切核酸酶促进靶向基因组修饰的方法和组合物
US20220348925A1 (en) 2019-09-09 2022-11-03 Scribe Therapeutics Inc. Compositions and methods for the targeting of sod1
US20230220425A1 (en) 2019-10-28 2023-07-13 Targetgene Biotechnologies Ltd Pam-reduced and pam-abolished cas derivatives compositions and uses thereof in genetic modulation
CN115175921A (zh) 2019-12-06 2022-10-11 斯克里贝治疗公司 颗粒递送系统
WO2021113769A1 (en) 2019-12-07 2021-06-10 Scribe Therapeutics Inc. Compositions and methods for the targeting of htt
KR20230002401A (ko) 2020-03-18 2023-01-05 스크라이브 테라퓨틱스 인크. C9orf72의 표적화를 위한 조성물 및 방법
KR20230128289A (ko) 2020-12-03 2023-09-04 스크라이브 테라퓨틱스 인크. 조작된 클래스 2 유형 v crispr 시스템

Also Published As

Publication number Publication date
US11560555B2 (en) 2023-01-24
TW202113074A (zh) 2021-04-01
WO2020247882A1 (en) 2020-12-10
IL288738A (en) 2022-02-01
SG11202113253SA (en) 2021-12-30
EP3980533A1 (en) 2022-04-13
KR20220032050A (ko) 2022-03-15
US20230124880A1 (en) 2023-04-20
PE20220256A1 (es) 2022-02-21
CA3142883A1 (en) 2020-12-10
AU2020289591A1 (en) 2021-12-23
US20220220508A1 (en) 2022-07-14
US20220081681A1 (en) 2022-03-17
CL2021003233A1 (es) 2022-08-12
JP2022534809A (ja) 2022-08-03
CN114375334A (zh) 2022-04-19
GB2600274A (en) 2022-04-27
BR112021024288A2 (pt) 2022-02-15

Similar Documents

Publication Publication Date Title
MX2021015058A (es) Sistemas de casx artificiales.
AU2018251801A8 (en) Novel type VI CRISPR orthologs and systems
MX2022010611A (es) Identificacion libre de bisulfito de modificaciones de citosina por resolucion de base.
MY194032A (en) Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof
MX2022001134A (es) Proteinas quimericas de factor viii y usos de estas.
PH12018501280A1 (en) Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
PH12017500022A1 (en) Carrier-antibody compositions and methods of making and using the same
MX2019007020A (es) Anticuerpos il-11.
IL281305A (en) Proteins that bind CD16, NKG2D, and CCR4, EGFR, or PD-L1
NZ759833A (en) Recombinant adenoviruses carrying transgenes
TR201909037T4 (tr) Yeni protein deamidaz.
PH12017502323A1 (en) Novel xylanase
ZA202202628B (en) Novel crispr dna targeting enzymes and systems
MX2020008272A (es) Nucleasas diseñadas específicas de blancos.
MX2019004487A (es) Metodos y composiciones para el tratamiento de la enfermedad de fabry.
MX2020013722A (es) Anticuerpos que comprenden polipeptido insertado en la region de marco 3.
EA201791918A1 (ru) Модификация белков клеток-хозяев
EA202190454A1 (ru) Новый crispr-ассоциированный белок и его применение
MX2022000425A (es) Metodos y composiciones que comprenden un nivel reducido de proteinas de celulas hospedadoras.
CA3063204A1 (en) Clotting factor variants and their use
MX2018000023A (es) Particulas semejantes a virus recombinantes que utilizan la proteina gag del virus de inmunodeficiencia bovina.
PH12018500468A1 (en) Fusion protein
MX2021009154A (es) Selectividad eficaz de proteinas recombinantes.
MX2021008983A (es) Atributos de aflibercept y metodos de caracterizacion y modificacion de los mismos.
WO2019012481A3 (en) G-QUADRUPLEXES DIVIDED FOR CAPTURE AND DETECTION OF NUCLEIC ACIDS